Angiogenesis inhibitors: current strategies and future prospects.
Angiogenesis inhibitors: current strategies and future prospects.
复制标题
DOI：
10.3322/caac.20075
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
Figg WD
中科院分区：
文献类型：
--
作者：
Cook KM;Figg WD
血管生成由于其在肿瘤生长中的关键作用而成为药物治疗的一个有吸引力的靶点。目前有大量的化合物处于临床前开发阶段，许多化合物现已进入临床和/或获得FDA批准。控制血管生成的几种调节和信号分子是令人感兴趣的，包括生长因子（例如VEGF、PDGF、FGF、EGF）、受体酪氨酸激酶、转录因子如HIF以及参与MAPK和PI 3 K信号传导的分子。已经确定了靶向这些途径的药理学药物，但对于某些药物（特别是沙利度胺），对抗肿瘤作用的具体机制的理解已被证明是难以捉摸的。以下综述描述了抗血管生成肿瘤治疗的关键分子机制和新疗法。
Angiogenesis has become an attractive target for drug therapy due to its key role in tumor growth. An extensive array of compounds is currently in pre-clinical development, with many now entering the clinic and/or achieving FDA approval. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (e.g. VEGF, PDGF, FGF, EGF), receptor tyrosine kinases, transcription factors such as HIF, as well as molecules involved in MAPK and PI3K signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of anti-tumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for anti-angiogenic tumor therapy.
登录
查看更多内容
影响因子：
78.5
作者：
Bartlett, JB;Dredge, K;Dalgleish, AG
通讯作者：
Dalgleish, AG
影响因子：
50.3
作者：
Blouw, B;Song, HQ;Bergers, G
通讯作者：
Bergers, G
影响因子：
5.8
作者：
Bauer, KS;Dixon, SC;Figg, WD
通讯作者：
Figg, WD
影响因子：
56.9
作者：
BROUTYBOYE, D;ZETTER, BR
通讯作者：
ZETTER, BR
影响因子：
158.5
作者：
Bonner, JA;Harari, PM;Ang, KK
通讯作者：
Ang, KK